KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myelomaSundar Jagannath, David S. Siegel, Kosei Matsue et al.|Blood Cancer Journal|2021Cited by 89
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of MyelofibrosisJuan Carlos Hernández‐Boluda, Irene Pastor‐Galán, Eduardo Arellano‐Rodrigo et al.|British Journal of Haematology|2022Cited by 16
The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosisAlberto Hernández‐Sánchez, Á. Villaverde-Ramiro, Eduardo Arellano‐Rodrigo et al.|American Journal of Hematology|2024Cited by 8
Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemiaGonzalo Carreño‐Tarragona, On behalf of the MPN Spanish Group (GEMFIN), Rodrigo Gil-Manso et al.|Leukemia|2026Cited by 0
Survival outcomes and treatment patterns in myelofibrosis in the <scp>JAK</scp> inhibitor eraJuan Carlos Hernández‐Boluda, the Spanish MPN Group (GEMFIN), Eduardo Arellano‐Rodrigo et al.|British Journal of Haematology|2026Cited by 0